Pristine sets new benchmark in in-clinic diagnostics with multi-modality precision and seamless workflow
Remidio Innovative Solutions has launched its dual brand strategy, Remidio and Pristine, to address the full spectrum of eye care needs, from last-mile screening to advanced clinical diagnostics.
The New Brand Architecture
- Remidio: “Remidio remains the mother brand, synonymous with its mission of eliminating preventable blindness through simplicity and innovation and advancing healthcare through the eye.
- Insta represents portable devices for outreach and primary screening to bring more people into care pathways.
- Pristine is dedicated to in-clinic, multi-modality devices that drive efficiency, precision, and deliver a seamless, high-performance diagnostic workflow.
Together, these brands serve the complete care continuum, from screening to diagnosis, from detection to decision-making.
“Having built tools that enabled early detection and brought more patients to specialists, the next step was inevitable, improving the efficiency of care once they arrive,” said Dr Anand Sivaraman, Founding Director and CEO, Remidio. “With Pristine, we’re equipping clinics to see more, do more, not just faster, but with greater clinical confidence.”
Pristine’s suite of in-clinic innovations is built to drive measurable efficiency.
- Pristine 1.5 reduces retina imaging time per patient through automated workflows.
- Pristine 5.0 offers true-colour, wide-field imaging in seconds, maximising throughput without compromising quality.
- The Pristine VX650 enables comprehensive, multimodal diagnostics in high-volume settings, streamlining the workup process across retina and refractive care.
- The to be launched Pristine OBM 12 delivers 12 essential eye measurements in just 25 seconds, empowering technicians to manage myopia and pre-operative evaluations with precision and minimal intervention.
